AB 1990 would tighten sourcing, testing and advertising rules for compounded GLP‑1 weight‑loss drugs in California, drawing sharp pushback from compounding pharmacies and patient advocates. The measure raises immediate questions about safety, access and cost.

A UCLA study finds unified financing could cut billions from California’s health bill — but federal waivers, ERISA and fraught political choices make implementation difficult.

Avenal’s recalled mayor and councilmembers have refused to vacate after an April recall, prompting a county cease‑and‑desist and a potential quo warranto lawsuit. State review is now underway.